关键词：安进,Onyx制药,收购

2013年8月7日讯 /生物谷BIOON/ --彭博社8月6日援引知情人士消息，医生在线答疑，安进（Amgen）有意提高其收购要约报价，好医师网，愿以每股130美元的出价收购Onyx制药。该知情人士透露，目前，安进的出价是最高的。

安进发言人和Onyx制药发言人均拒绝发表评论。

此前，Onyx制药曾拒绝了来自安进（Amgen）主动提出的100亿美元收购要约，当时安进提出的收购要约为每股全现金120美元，但Onyx制药董事会认为，安进的报价严重低估了该公司的价值和前景。之后，Onyx制药在6月份表示，正在寻求其他潜在买家的收购。

彭博社7月22日报道称，阿斯利康（AZN）、辉瑞（Pfizer）、诺华（Novartis）也有意竞标Onyx制药。

据分析师预计，竞标的赢家将获得Onyx制药的血癌药物Kyprolis，截止2019年，该药的销售可能会飙升9倍至24亿美元。

Onyx制药其他产品包括抗癌药物多吉美（Nexavar，用于肝癌和肾癌治疗）和Stivarga（用于胃癌治疗），该公司2012年收入3.62亿美元，80%销售来自这2个药物。（生物谷Bioon.com）

英文原文：Amgen seen raising bid to acquire Onyx Pharmaceuticals: report

Tue Aug 6, 2013 5:02pm EDT (Reuters) - Amgen Inc is expected to sweeten its offer to acquire Onyx Pharmaceuticals Inc to $130 per share after its previous bid was rejected as too low, Bloomberg reported on Tuesday, citing a person familiar with the matter.

After Amgen's unsolicited offer of $120 per share was turned down, Onyx said in June it was seeking takeover bids from other potential buyers.

The $130 offer is currently the highest bid on the table for Onyx, according the anonymous source, the report said.

A spokeswoman for Amgen, the world's largest biotechnology company, declined to comment on the report. Onyx also declined to comment.

The purchase would give Amgen full rights to Onyx's new blood cancer drug Kyprolis, as well as revenue from Nexavar, a kidney and liver cancer drug Onyx shares with German drugmaker Bayer AG.

Onyx shares closed at $132.02 on Nasdaq on Tuesday. They had traded as high as $136.87 last month in a clear indication that investors are betting a takeover will come at a higher price.

(责任编辑：lilizhao)

您还可以这样阅读